{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:26:44Z","timestamp":1790526404019,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T00:00:00Z","timestamp":1574812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T00:00:00Z","timestamp":1574812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s11864-019-0684-8","type":"journal-article","created":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T06:02:36Z","timestamp":1574834556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Leukemic Non-nodal Mantle Cell Lymphoma: Diagnosis and Treatment"],"prefix":"10.1007","volume":"20","author":[{"given":"Akriti Gupta","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Che","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarfraz","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahram","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,27]]},"reference":[{"issue":"8","key":"684_CR1","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","volume":"16","author":"JO Armitage","year":"1998","unstructured":"Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin\u2019s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin\u2019s lymphoma classification project. J Clin Oncol. 1998;16(8):2780\u201395.","journal-title":"J Clin Oncol"},{"issue":"19","key":"684_CR2","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","volume":"117","author":"E Campo","year":"2011","unstructured":"Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019\u201332.","journal-title":"Blood."},{"issue":"20","key":"684_CR3","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood."},{"issue":"10","key":"684_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11912-018-0728-4","volume":"20","author":"A Condoluci","year":"2018","unstructured":"Condoluci A, Rossi D, Zucca E, Cavalli F. Toward a risk-tailored therapeutic policy in mantle cell lymphoma. Curr Oncol Rep. 2018;20(10):79.","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"684_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/hon.855","volume":"26","author":"G Barna","year":"2008","unstructured":"Barna G, Reiniger L, T\u00e1trai P, Kopper L, Matolcsy A. The cut-off levels of CD23 expression in the differential diagnosis of MCL and CLL. Hematol Oncol. 2008;26(3):167\u201370.","journal-title":"Hematol Oncol"},{"issue":"5","key":"684_CR6","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.semcancer.2011.09.007","volume":"21","author":"C Royo","year":"2011","unstructured":"Royo C, Salaverria I, Hartmann EM, Rosenwald A, Campo E, Be\u00e0 S. The complex landscape of genetic alterations in mantle cell lymphoma. Semin Cancer Biol. 2011;21(5):322\u201334.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"684_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13046-017-0652-8","volume":"36","author":"H Ye","year":"2017","unstructured":"Ye H, Desai A, Zeng D, Nomie K, Romaguera J, Ahmed M, et al. Smoldering mantle cell lymphoma. J Exp Clin Cancer Res. 2017;36(1):185.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"684_CR8","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/sj.thj.6200111","volume":"2","author":"E Vizcarra","year":"2001","unstructured":"Vizcarra E, Mart\u00ednez-Climent JA, Benet I, Marugan I, Terol MJ, Prosper F, et al. Identification of two subgroups of mantle cell leukemia with distinct clinical and biological features. Hematol J. 2001;2(4):234\u201341.","journal-title":"Hematol J"},{"issue":"10","key":"684_CR9","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1053\/S0046-8177(03)00410-6","volume":"34","author":"L Nodit","year":"2003","unstructured":"Nodit L, Bahler DW, Jacobs SA, Locker J, Swerdlow SH. Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Hum Pathol. 2003;34(10):1030\u20134.","journal-title":"Hum Pathol"},{"issue":"11","key":"684_CR10","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.humpath.2005.08.021","volume":"36","author":"B Espinet","year":"2005","unstructured":"Espinet B, Sol\u00e9 F, Pedro C, Garcia M, Bellosillo B, Salido M, et al. Clonal proliferation of cyclin D1-positive mantle lymphocytes in an asymptomatic patient: an early-stage event in the development or an indolent form of a mantle cell lymphoma? Hum Pathol. 2005;36(11):1232\u20137.","journal-title":"Hum Pathol"},{"issue":"4","key":"684_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1182\/blood-2018-05-853077","volume":"132","author":"P Martin","year":"2018","unstructured":"Martin P. A tale of two mantle cell lymphomas. Blood. 2018;132(4):347\u20138.","journal-title":"Blood."},{"issue":"3","key":"684_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3109\/10428194.2010.534518","volume":"52","author":"S Sachanas","year":"2011","unstructured":"Sachanas S, Pangalis GA, Vassilakopoulos TP, Korkolopoulou P, Kontopidou FN, Athanasoulia M, et al. Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen. Leuk Lymphoma. 2011;52(3):387\u201393.","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"684_CR13","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","volume":"27","author":"P Martin","year":"2009","unstructured":"Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27(8):1209\u201313.","journal-title":"J Clin Oncol"},{"issue":"8","key":"684_CR14","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1038\/leu.2012.72","volume":"26","author":"C Royo","year":"2012","unstructured":"\u2022 Royo C, Navarro A, Clot G, et al. Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia. 2012;26(8):1895\u20138 This paper describes that in non-nodal type of MCL, the presence of specific genetic anomalies identified disease progression risk. The presence of 17p\/TP53 alterations was consistent with more aggressive disease.","journal-title":"Leukemia"},{"issue":"4","key":"684_CR15","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","volume":"70","author":"V Fern\u00e0ndez","year":"2010","unstructured":"Fern\u00e0ndez V, Salamero O, Espinet B, Sol\u00e9 F, Royo C, Navarro A, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010;70(4):1408\u201318.","journal-title":"Cancer Res"},{"issue":"12","key":"684_CR16","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.1182\/blood-2002-06-1864","volume":"101","author":"J Orchard","year":"2003","unstructured":"Orchard J, Garand R, Davis Z, Babbage G, Sahota S, Matutes E, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood. 2003;101(12):4975\u201381.","journal-title":"Blood."},{"issue":"8","key":"684_CR17","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3324\/haematol.2010.036277","volume":"96","author":"SL Ondrejka","year":"2011","unstructured":"\u2022 Ondrejka SL, Lai R, Smith SD, Hsi ED. Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica. 2011;96(8):1121\u20137 This paper emphasizes that mantle cell lymphoma can present with disease limited to blood and the bone marrow, and the recognition of this variant could help treatment decision and possibly avoid unnecessary treatment.","journal-title":"Haematologica"},{"key":"684_CR18","first-page":"397\u2013414.e7","volume-title":"Hematopathology","author":"E Campo","year":"2016","unstructured":"Campo E, Jares P. Mantle cell lymphoma. In: Jaffe ES, Arber DA, Quintanilla-Martinez L, Campo E, Harris NL, editors. Hematopathology, vol. 2, Chapter 22. Amsterdam: Elsevier; 2016. p. 397\u2013414.e7."},{"issue":"3","key":"684_CR19","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0092-8674(03)00570-1","volume":"114","author":"J Lamb","year":"2003","unstructured":"Lamb J, Ramaswamy S, Ford HL, Contreras B, Martinez RV, Kittrell FS, et al. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell. 2003;114(3):323\u201334.","journal-title":"Cell."},{"issue":"7350","key":"684_CR20","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nature10155","volume":"474","author":"S Jirawatnotai","year":"2011","unstructured":"Jirawatnotai S, Hu Y, Michowski W, et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature. 2011;474(7350):230\u20134.","journal-title":"Nature."},{"issue":"21","key":"684_CR21","doi-asserted-by":"publisher","first-page":"8802","DOI":"10.1158\/0008-5472.CAN-10-0312","volume":"70","author":"Z Li","year":"2010","unstructured":"Li Z, Jiao X, Wang C, Shirley LA, Elsaleh H, Dahl O, et al. Alternative cyclin D1 splice forms differentially regulate the DNA damage response. Cancer Res. 2010;70(21):8802\u201311.","journal-title":"Cancer Res"},{"issue":"8","key":"684_CR22","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1182\/blood-2012-08-452284","volume":"121","author":"I Salaverria","year":"2013","unstructured":"Salaverria I, Royo C, Carvajal-Cuenca A, Clot G, Navarro A, Valera A, et al. CCND2 rearrangements are the most frequent genetic events in cyclin D1(\u2212) mantle cell lymphoma. Blood. 2013;121(8):1394\u2013402.","journal-title":"Blood."},{"issue":"12","key":"684_CR23","doi-asserted-by":"publisher","first-page":"5422","DOI":"10.1182\/blood-2006-11-057208","volume":"109","author":"M Pinyol","year":"2007","unstructured":"Pinyol M, Bea S, Pl\u00e0 L, Ribrag V, Bosq J, Rosenwald A, et al. Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis. Blood. 2007;109(12):5422\u20139.","journal-title":"Blood."},{"issue":"1","key":"684_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0002-9440(10)65558-7","volume":"153","author":"L Quintanilla-Martinez","year":"1998","unstructured":"Quintanilla-Martinez L, Thieblemont C, Fend F, Kumar S, Pinyol M, Campo E, et al. Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor. Am J Pathol. 1998;153(1):175\u201382.","journal-title":"Am J Pathol"},{"issue":"20","key":"684_CR25","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","volume":"72","author":"A Navarro","year":"2012","unstructured":"Navarro A, Clot G, Royo C, Jares P, Hadzidimitriou A, Agathangelidis A, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012;72(20):5307\u201316.","journal-title":"Cancer Res"},{"issue":"12","key":"684_CR26","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1182\/blood-2012-06-438937","volume":"121","author":"MC Vegliante","year":"2013","unstructured":"Vegliante MC, Palomero J, P\u00e9rez-Gal\u00e1n P, Rou\u00e9 G, Castellano G, Navarro A, et al. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood. 2013;121(12):2175\u201385.","journal-title":"Blood."},{"issue":"14","key":"684_CR27","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1182\/blood-2014-04-569566","volume":"124","author":"J Palomero","year":"2014","unstructured":"Palomero J, Vegliante MC, Rodr\u00edguez ML, Eguileor A, Castellano G, Planas-Rigol E, et al. SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma. Blood. 2014;124(14):2235\u201347.","journal-title":"Blood."},{"issue":"11","key":"684_CR28","doi-asserted-by":"publisher","first-page":"4445","DOI":"10.1182\/blood-2004-10-3907","volume":"105","author":"F Rubio-Moscardo","year":"2005","unstructured":"Rubio-Moscardo F, Climent J, Siebert R, Piris MA, Mart\u00edn-Subero JI, Niel\u00e4nder I, et al. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood. 2005;105(11):4445\u201354.","journal-title":"Blood."},{"issue":"4","key":"684_CR29","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.anndiagpath.2014.03.006","volume":"18","author":"J Chapman-Fredricks","year":"2014","unstructured":"Chapman-Fredricks J, Sandoval-Sus J, Vega F, Lossos IS. Progressive leukemic non-nodal mantle cell lymphoma associated with deletions of TP53, ATM, and\/or 13q14. Ann Diagn Pathol. 2014;18(4):214\u20139 In this study, the authors identified three cases of leukemic, non-nodal-MCL in which TP53, ATM, and\/or 13q14 deletions were identified and had an aggressive disease course.","journal-title":"Ann Diagn Pathol"},{"issue":"5","key":"684_CR30","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","volume":"126","author":"MH Delfau-Larue","year":"2015","unstructured":"\u2022\u2022 Delfau-Larue MH, Klapper W, Berger F, et al. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood. 2015;126(5):604\u201311 This study demostrates that high-dose cytarabine was ineffective in MCL patients with deletions of CDKN2A (p16) or TP53, and thus should be candidates for alternative therapeutic strategies.","journal-title":"Blood"},{"issue":"17","key":"684_CR31","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","volume":"130","author":"CW Eskelund","year":"2017","unstructured":"\u2022\u2022 Eskelund CW, Dahl C, Hansen JW, et al. Mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130(17):1903\u201310 This paper reports that TP53 mutations identify a phenotypically distinct and highly aggressive form of MCL with poor or no response to the standard chemotherapies and autologous stem-cell transplantation.","journal-title":"Blood"},{"issue":"6","key":"684_CR32","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","volume":"126","author":"ML Wang","year":"2015","unstructured":"Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739\u201345.","journal-title":"Blood."},{"issue":"6","key":"684_CR33","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"\u2022\u2022 Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507\u201316 This study established the BTK inhibitor ibrutinib as a highly active agent showing durable single-agent activity in the relapsed and refractory mantle-cell lymphoma.","journal-title":"N Engl J Med"},{"issue":"2","key":"684_CR34","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1016\/j.clml.2018.11.007","volume":"19","author":"S Mori","year":"2019","unstructured":"Mori S, Patel RD, Ahmad S, et al. Aggressive leukemic non-nodal mantle cell lymphoma with P53 gene rearrangement\/mutation is highly responsive to rituximab\/ibrutinib combination therapy. Clin Lymphoma Myeloma Leuk. 2019;19(2):e93\u20137.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"684_CR35","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s00277-014-2087-z","volume":"93","author":"WH Kr\u00fcger","year":"2014","unstructured":"Kr\u00fcger WH, Hirt C, Basara N, Sayer HG, Behre G, Fischer T, et al. Allogeneic stem cell transplantation for mantle cell lymphoma--final report from the prospective trials of the East German Study Group Haematology\/oncology (OSHO). Ann Hematol. 2014;93(9):1587\u201397.","journal-title":"Ann Hematol"},{"issue":"7","key":"684_CR36","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"M Dreyling","year":"2005","unstructured":"Dreyling M, Lenz G, Hoster E, van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL network. Blood. 2005;105(7):2677\u201384.","journal-title":"Blood."},{"issue":"4","key":"684_CR37","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","volume":"131","author":"SM Aukema","year":"2018","unstructured":"Aukema SM, Hoster E, Rosenwald A, Canoni D, Delfau-Larue MH, Rymkiewicz G, et al. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. Blood. 2018;131(4):417\u201320.","journal-title":"Blood."},{"issue":"4","key":"684_CR38","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1158\/1078-0432.CCR-13-1077","volume":"20","author":"B Espinet","year":"2014","unstructured":"Espinet B, Ferrer A, Bellosillo B, Nonell L, Salar A, Fern\u00e1ndez-Rodr\u00edguez C, et al. Distinction between asymptomatic monoclonal B-cell lymphocytosis with cyclin D1 overexpression and mantle cell lymphoma: from molecular profiling to flow cytometry. Clin Cancer Res. 2014;20(4):1007\u201319.","journal-title":"Clin Cancer Res"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-019-0684-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-019-0684-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-019-0684-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T01:34:45Z","timestamp":1606354485000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-019-0684-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,27]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["684"],"URL":"https:\/\/doi.org\/10.1007\/s11864-019-0684-8","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,27]]},"assertion":[{"value":"27 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Akriti Gupta Jain, Chung-Che Chang, Sarfraz Ahmad, and Shahram Mori declare they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"85"}}